Australia - English - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - glecaprevir, quantity: 100 mg; pibrentasvir, quantity: 40 mg - tablet, film coated - excipient ingredients: propylene glycol monocaprylate; tocofersolan; croscarmellose sodium; sodium stearylfumarate; copovidone; colloidal anhydrous silica; titanium dioxide; lactose monohydrate; hypromellose; iron oxide red; macrogol 3350 - maviret is indicated for the treatment of adult and paediatric patients 3 years and older with chronic hepatitis c virus (hcv) genotype (gt) 1, 2, 3, 4, 5, or 6 infection with or without compensated cirrhosis. this includes patients with hcv gt1 infection who were previously treated with either a regimen of an ns5a inhibitor or with an ns3/4a protease inhibitor but not both classes of inhibitors (see 4.2 dose and method of administration and 5.1 pharmacodynamic properties ? clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - glecaprevir, quantity: 100 mg; pibrentasvir, quantity: 40 mg - tablet, film coated - excipient ingredients: propylene glycol monocaprylate; tocofersolan; croscarmellose sodium; sodium stearylfumarate; copovidone; colloidal anhydrous silica; titanium dioxide; lactose monohydrate; hypromellose; iron oxide red; macrogol 3350 - maviret is indicated for the treatment of adult and paediatric patients 3 years and older with chronic hepatitis c virus (hcv) genotype (gt) 1, 2, 3, 4, 5, or 6 infection with or without compensated cirrhosis. this includes patients with hcv gt1 infection who were previously treated with either a regimen of an ns5a inhibitor or with an ns3/4a protease inhibitor but not both classes of inhibitors (see 4.2 dose and method of administration and 5.1 pharmacodynamic properties ? clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - glecaprevir, quantity: 50 mg; pibrentasvir, quantity: 20 mg - granules - excipient ingredients: copovidone; tocofersolan; propylene glycol monocaprylate; colloidal anhydrous silica; croscarmellose sodium; sodium stearylfumarate; purified water; titanium dioxide; lactose monohydrate; hypromellose; iron oxide red; macrogol 3350; iron oxide yellow - maviret is indicated for the treatment of adult and paediatric patients 3 years and older with chronic hepatitis c virus (hcv) genotype (gt) 1, 2, 3, 4, 5, or 6 infection with or without compensated cirrhosis. this includes patients with hcv gt1 infection who were previously treated with either a regimen of an ns5a inhibitor or with an ns3/4a protease inhibitor but not both classes of inhibitors (see 4.2 dose and method of administration and 5.1 pharmacodynamic properties ? clinical trials).

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

abbvie sdn bhd - glecaprevir; pibrentasvir -

United States - English - NLM (National Library of Medicine)

abbvie inc. - pibrentasvir (unii: 2wu922tk3l) (pibrentasvir - unii:2wu922tk3l), glecaprevir (unii: k6buu8j72p) (glecaprevir - unii:k6buu8j72p) - pibrentasvir 40 mg - mavyret is indicated for the treatment of adult and pediatric patients 3 years and older with chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis (child-pugh a). mavyret is indicated for the treatment of adult and pediatric patients 3 years and older with hcv genotype 1 infection, who previously have been treated with a regimen containing an hcv ns5a inhibitor or an ns3/4a protease inhibitor (pi), but not both [see dosage and administration ( 2.2 ) and clinical studies ( 14 )].   - mavyret is contraindicated in patients with moderate or severe hepatic impairment (child-pugh b or c) or those with any history of prior hepatic decompensation [see warnings and precautions ( 5.2 ), use in specific populations ( 8.7 ) and clinical pharmacology ( 12.3 )] . - mavyret is contraindicated with atazanavir or rifampin [see drug interaction ( 7.3 ) and clinical pharmacology ( 12.3 )] . risk summary no adequate human data are available to establish whether

European Union - English - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - glecaprevir, pibrentasvir - hepatitis c, chronic - antivirals for systemic use - maviret is indicated for the treatment of chronic hepatitis c virus (hcv) infection in adults and children aged 3 years and older.maviret coated granules is indicated for the treatment of chronic hepatitis c virus (hcv) infection in children 3 years and older.

Israel - English - Ministry of Health

abbvie biopharmaceuticals ltd, israel - glecaprevir; pibrentasvir - film coated tablets - pibrentasvir 40 mg; glecaprevir 100 mg - glecaprevir and pibrentasvir - maviret is indicated for the treatment of chronic hepatitis c virus (hcv) infection in adults and in adolescents aged 12 to <18 years

Israel - English - Ministry of Health

abbvie biopharmaceuticals ltd, israel - glecaprevir; pibrentasvir - film coated tablets - pibrentasvir 40 mg; glecaprevir 100 mg - glecaprevir and pibrentasvir - maviret is indicated for the treatment of chronic hepatitis c virus (hcv) infection in adults and in adolescents aged 12 to <18 years

Singapore - English - HSA (Health Sciences Authority)

abbvie pte. ltd. - glecaprevir; pibrentasvir - tablet, film coated - glecaprevir 100.0 mg; pibrentasvir 40.0 mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

abbvie ltd - glecaprevir; pibrentasvir - oral tablet - 100mg ; 40mg